×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
合肥物质科学研究院 [9]
内容类型
期刊论文 [9]
发表日期
2022 [6]
2021 [1]
2020 [1]
2019 [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共9条,第1-9条
帮助
限定条件
专题:合肥物质科学研究院
第一署名单位
第一作者单位
通讯作者单位
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review
期刊论文
TRANSLATIONAL CANCER RESEARCH, 2022
作者:
He, Libin
;
Shen, Xiabo
;
Liu, Yiyuan
;
Gao, Lu
;
Wu, Jiayi
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2022/12/23
Advanced human epidermal growth factor receptor 2-positive breast cancer (advanced HER2-positive breast cancer)
apatinib
case report
The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
期刊论文
CANCER MEDICINE, 2022
作者:
Yu, Xiaoqing
;
Si, Jinfei
;
Wei, Jingwen
;
Wang, Yanling
;
Sun, Yan
收藏
  |  
浏览/下载:20/0
  |  
提交时间:2022/12/23
EGFR-TKIs
non-small cell lung cancer (NSCLC)
real-world study
survival outcome
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
期刊论文
FRONTIERS IN PHARMACOLOGY, 2022, 卷号: 13
作者:
Wu, Xiaofan
;
Yang, Hongjian
;
Yu, Xingfei
;
Qin, Jiang-Jiang
收藏
  |  
浏览/下载:18/0
  |  
提交时间:2022/12/22
HER2
breast cancer
targeted therapy
drug resistance
overcoming strategies
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
期刊论文
LIVER CANCER, 2022, 卷号: 11
作者:
Sun, Yongkun
;
Zhang, Wen
;
Bi, Xinyu
;
Yang, Zhengqiang
;
Tang, Yu
收藏
  |  
浏览/下载:34/0
  |  
提交时间:2022/12/23
Chinese interdisciplinary experts
Hepatocellular carcinoma
Molecular targeted therapy
Consensus
Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
期刊论文
BMC PULMONARY MEDICINE, 2022, 卷号: 22
作者:
Wang, Wenxian
;
Shao, Lan
;
Xu, Yibing
;
Song, Zhengbo
;
Lou, Guangyuan
收藏
  |  
浏览/下载:18/0
  |  
提交时间:2022/12/23
Non-small cell lung cancer
Prognosis
Angiogenesis
Tyrosine kinase inhibitors
Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study
期刊论文
GENES CHROMOSOMES & CANCER, 2022
作者:
Wang, Wenxian
;
Gu, Xiaodong
;
Si, Jinfei
;
Pu, Xingxiang
;
Wang, Liping
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2022/05/16
BRAF mutation
immune checkpoint inhibitors
non-small cell lung cancer
PD-L1
targeted therapy
The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
期刊论文
TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10
作者:
Pan, Guoqiang
;
Chen, Kaiyan
;
Yu, Xiaoqing
;
Sheng, Jiamin
;
Fan, Yun
收藏
  |  
浏览/下载:38/0
  |  
提交时间:2021/11/01
Non-small cell lung cancer (NSCLC)
T790M abundance
droplet digital PCR (ddPCR)
next generation sequencing (NGS)
osimertinib
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation
期刊论文
ONCOGENE, 2020, 卷号: 39
作者:
Jin, Ying
;
Bao, Hua
;
Le, Xiuning
;
Fan, Xiaojun
;
Tang, Ming
收藏
  |  
浏览/下载:26/0
  |  
提交时间:2020/11/26
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)
期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:
Wu, Jiaxin
;
Wang, Aoli
;
Li, Xixiang
;
Chen, Cheng
;
Qi, Ziping
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2019/11/27
BCR-ABL
PDGFR
chronic myeloid leukemia
kinase inhibitor
©版权所有 ©2017 CSpace - Powered by
CSpace